CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
CORCEPT THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$112.10+1.94 (+1.76%)
Close on Oct 19, 2026
- Market cap
- $13.27B
- P/E (TTM)
- 266.9
- Dividend yield
- –
Corcept Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Market Cap | $12.12B | $197.05M |
| Enterprise Value | $11.81B | $106.56M |
| PE Ratio | 266.90 | 20.52 |
| PS Ratio | 14.59 | 3.93 |
| PB Ratio | 17.17 | 2.14 |
| P/TBV Ratio | 17.17 | 2.46 |
| P/FCF Ratio | 113.33 | 18.25 |
| P/OCF Ratio | 110.46 | 13.78 |
Enterprise value
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 14.21 | 2.69 |
| EV / EBITDA | 1460.87 | 14.86 |
| EV / EBIT | 1843.81 | 19.00 |
| EV / FCF | 110.45 | 21.02 |
Income (trailing twelve months)
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Revenue | $830.81M | $57.94M |
| Gross Profit | $816.73M | $90.47M |
| Operating Income | $6.41M | -$21.44M |
| Pretax Income | $26.37M | -$14.45M |
| Net Income | $55.18M | -$22.46M |
| EBITDA | $8.08M | -$16.91M |
| EPS (Diluted) | $0.42 | -$0.83 |
Margins
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 98.3% | 52.3% |
| Operating Margin | 0.77% | -44.5% |
| Pretax Margin | 3.17% | -13.0% |
| Profit Margin | 6.64% | -39.2% |
| EBITDA Margin | 0.97% | -31.3% |
| FCF Margin | 12.9% | -8.85% |
Returns
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 8.23% | -53.1% |
| Return on Assets (ROA) | 6.53% | -41.0% |
| Return on Invested Capital (ROIC) | 1.85% | -32.0% |
| Return on Capital Employed (ROCE) | 0.87% | -37.8% |
Growth
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 16.0% | 6.01% |
| Net Income Growth (YoY) | -58.7% | -37.7% |
| EPS Growth (YoY) | -62.5% | -29.2% |
| FCF Growth (YoY) | -40.8% | 2.34% |
| Revenue Growth (3Y CAGR) | 23.7% | 2.25% |
| Revenue Growth (5Y CAGR) | 16.6% | 6.42% |
| EPS Growth (3Y CAGR) | -1.95% | -0.17% |
| EPS Growth (5Y CAGR) | -0.72% | 3.77% |
Balance sheet
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $308.20M | $62.42M |
| Net Cash (Debt) | $308.20M | $15.68M |
| Net Cash Per Share | $2.85 | $0.65 |
| Equity (Book Value) | $705.78M | $48.79M |
| Book Value Per Share | $6.53 | $1.36 |
| Tangible Book Value | $705.78M | $23.06M |
| Working Capital | $285.87M | $75.77M |
Financial position
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.86 | 3.30 |
| Quick Ratio | 2.50 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $109.70M | -$12.35M |
| Capital Expenditures | -$2.78M | -$1.06M |
| Free Cash Flow | $106.92M | -$20.28M |
| FCF Per Share | $0.99 | -$0.41 |
Efficiency
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.98 | 0.38 |
| Inventory Turnover | 1.11 | 2.67 |
| Revenue Per Employee | $1.14M | $398.96K |
| Profits Per Employee | $75.59K | -$732.08K |
| Employee Count | 730 | 73 |
Dividends and yields
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 0.46% | -21.2% |
| FCF Yield | 0.88% | -7.64% |
| Buyback Yield | 0.35% | -0.58% |
| Shareholder Yield | 0.35% | 0.00% |
Shares
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 108,098,000 | 59,128,900 |
| Shares Change (YoY) | -2.32% | 11.1% |
| Float | 92,490,800 | 48,744,500 |
| Shares Held by Insiders | 14.4% | 11.8% |
| Shares Held by Institutions | 76.2% | 59.4% |
Taxes
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$28.81M | $91.50K |
| Effective Tax Rate | -109.3% | 20.6% |
Scores
| Measure | Corcept Therapeutics | Industry median |
|---|---|---|
| Graham Number | $7.85 | $17.36 |
| Graham Upside | -93.0% | -45.5% |
| Altman Z-Score | 42.12 | 0.10 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.81 | -2.62 |
Calculated by StockData from Corcept Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.